Allergic Rhinitis and Its Impact on Asthma

Bousquet, Jean; Cauwenberge, Paul Van; Khaltaev, Nikolaï

doi:10.1067/mai.2001.118891

Cited by 2,980 publications

(2,444 citation statements)

References 2,311 publications

Supporting

Mentioning

2,197

Contrasting

Unclassified

121

Order By: Relevance

“…Well‐controlled asthma was defined as an ACQ score ≤ 0.75 and not well‐controlled asthma as an ACQ score ≥ 1.5 26. The severity of rhinitis was graded according to ARIA guidelines 27.…”

Section: Methodsmentioning

confidence: 99%

Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea

Serrano-Pariente

Plaza

Soriano

et al. 2016

Allergy

View full text Add to dashboard Cite

BackgroundContinuous positive airway pressure (CPAP) in asthma patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a favorable impact on asthma, but data are inconsistent due to methodological limitations of previous studies.MethodsProspective, multicenter study. We examined asthma outcomes after 6 months of CPAP in 99 adult asthma patients (mean age 57 years) with OSAS (respiratory disturbance index ≥20). Asthma control and quality of life were assessed with the Asthma Control Questionnaire (ACQ) and the Mini Asthma Quality of Life Questionnaire (MiniAQLQ), respectively. Data were analyzed by intention‐to‐treat basis.ResultsThe mean ± SD score of the ACQ decreased from 1.39 ± 0.91 at baseline to 1.0 ± 0.78 at 6 months (P = 0.003), the percentage of patients with uncontrolled asthma from 41.4% to 17.2% (P = 0.006), and the percentage of patients with asthma attacks in the 6 months before and after treatment from 35.4% to 17.2% (P = 0.015). The score of the mAQLQ increased from 5.12 ± 1.38 to 5.63 ± 1.17 (P = 0.009). There were also significant improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversibility, and exhaled nitric oxide values (all P < 0.05). No significant changes were observed in drug therapy for asthma or their comorbidities nor in the patients’ weight.ConclusionsAsthma control (both actual and future risk), quality of life, and lung function improved after starting continuous positive airway pressure in asthmatics with moderate to severe obstructive sleep apnea syndrome.

show abstract

Section: Methodsmentioning

confidence: 99%

Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea

Serrano-Pariente

Plaza

Soriano

et al. 2016

Allergy

View full text Add to dashboard Cite

show abstract

“…19 The 2001 Allergic Rhinitis and Its Impact on Asthma (ARIA) Workgroup and World Health Organization document states that immunotherapy, including SLIT, should be initiated early in the disease process, but minimum age for onset of treatment is not specified. 20 The 2003 Joint Task Force position paper of the American College of Asthma, Allergy and Immunology and the American Academy of Allergy, Asthma and Immunology mentions age at onset of immunotherapy as a clinical problem of "cooperation." 21 Thus, the position that "there is no absolute cut-off .…”

Section: Introductionmentioning

confidence: 99%

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

Fiocchi¹,

Pajno

Grutta³

et al. 2005

Annals of Allergy, Asthma & Immunology

113

View full text Add to dashboard Cite

Background:The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years.Objective: To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years.Methods: Sixty-five children (51 boys and 14 girls; age range, 38 -80 months; mean Ϯ SD age, 60 Ϯ 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60 months old and children 61 to 80 months old.Results: The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and 7 in the older than 60 months age group, with no differences between these 2 groups.Conclusion: High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young children.Ann Allergy Asthma Immunol. 2005;95:254-258.

show abstract

“…In contrast, the use of second-generation H 1 antihistamines for relief of symptoms in seasonal/intermittent and perennial/persistent allergic rhinoconjunctivitis and chronic urticaria is supported by hundreds of appropriately randomized, double-masked, placebo-controlled clinical trials lasting weeks or months, in which inclusion criteria and exclusion criteria are clearly stated, an adequate number of participants is enrolled, and attrition and adherence are appropriately documented. Second-generation H 1 antihistamines are therefore the H 1 antihistamines of choice in the treatment of allergic rhinitis, allergic conjunctivitis, and chronic urticaria [2-5,13-16]. …”

Section: Efficacy Of H1 Antihistamines In Allergic Diseasesmentioning

confidence: 99%

“…To provide increased relief of nasal congestion, H 1 antihistamines are sometimes marketed in fixed-dose combinations with pseudoephedrine or other decongestants. H 1 antihistamines are less efficacious than intranasal glucocorticoids, especially for relief of nasal congestion [2,3,14,16]. …”

Section: Efficacy Of H1 Antihistamines In Allergic Diseasesmentioning

confidence: 99%

H1 Antihistamines: Current Status and Future Directions

Simon

Simons

2008

World Allergy Organization Journal

102

107

View full text Add to dashboard Cite

In this review, we compare and contrast the clinical pharmacology, efficacy, and safety of first-generation H1 antihistamines and second-generation H1 antihistamines. First-generation H1 antihistamines cross the blood-brain barrier, and in usual doses, they potentially cause sedation and impair cognitive function and psychomotor performance. These medications, some of which have been in use for more than 6 decades, have never been optimally investigated. Second-generation H1 antihistamines such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine cross the blood-brain barrier to a significantly smaller extent than their predecessors. The clinical pharmacology, efficacy, and safety of these medications have been extensively studied. They are therefore the H1 antihistamines of choice in the treatment of allergic rhinitis, allergic conjunctivitis, and urticaria. In the future, clinically advantageous H1 antihistamines developed with the aid of molecular techniques might be available.

show abstract

Allergic Rhinitis and Its Impact on Asthma

Cited by 2,980 publications

References 2,311 publications

Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea

Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

H1 Antihistamines: Current Status and Future Directions

Contact Info

Product

Resources

About